Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 30 for:    IGFBP2

IGF Binding Protein-2 Associated With Cognitive Decline

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03946930
Recruitment Status : Recruiting
First Posted : May 13, 2019
Last Update Posted : May 13, 2019
Sponsor:
Information provided by (Responsible Party):
Timothy Kwok, Chinese University of Hong Kong

Brief Summary:

There is lack of information on the risk factors of accelerated cognitive decline in older people with Alzheimer disease (AD). The extent of neurodegeneration and white matter disease has been reported to be important factors. In addition there may be biomarkers e.g. inflammatory cytokines that can contribute to cognitive decline. The impact of care arrangement and physical activity may also be important. Insulin signaling is impaired in Alzheimer disease (AD). Insulin and Insulin growth factor (IGF) pathways are closely related. IGF in the brain is in turn modulated especially by IGF binding protein -2. Higher plasma IGF binding protein -2 was associated with brain atrophy in older people.

We therefore propose to perform a cohort study to test the hypothesis that higher plasma IGF binding protein-2 is independently associated with greater cognitive decline in older people with AD. This will be based on an on-going AD registry which was designed to identify genetic biomarkers for AD. Detailed neurocognitive tests and lifestyle information are available. In addition, volumetric MRI brain scans were performed in all AD subjects. The hypothesis is that MRI brain volumes, serum biomarkers, physical activity, physical functioning are independently associated with cognitive decline in older people with AD. The objective is to identify risk factors of accelerated cognitive decline so that preventive measures can be designed to delay dependency in AD.


Condition or disease
Alzheimer Disease

Layout table for study information
Study Type : Observational
Estimated Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Is IGF Binding Protein -2 Associated With Cognitive Decline in Older People With Alzeimer Disease?
Actual Study Start Date : December 13, 2018
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Alzheimer's Disease Assessment Scale-cognitive subscale ADAS-COG [ Time Frame: 24-Months ]
    Cognitive assessment for dementia

  2. plasma IGF binding protein -2 [ Time Frame: 24 Months ]
    Blood test



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years to 90 Years   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subjects are recruited from the geriatric outpatient clinics or memory clinic.
Criteria

Inclusion Criteria:

  • Sufficient Cantonese competency for cognitive test
  • Clinical diagnosis of AD
  • FAST test staging 3-5

Exclusion Criteria:

  • Subjects who refuse blood taking procedure
  • No reliable family caregiver informant (person contact at least once a month)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03946930


Contacts
Layout table for location contacts
Contact: Timothy Kwok, MD +852 35053145 tkwok@cuhk.edu.hk
Contact: Hazel Mok, BSc +852 35053990 hazelmok@cuhk.edu.hk

Locations
Layout table for location information
Hong Kong
The Chinese University of Hong Kon Recruiting
Hong Kong, Hong Kong
Contact: Timothy Kwok, MD    +852 35053145    tkwok@cuhk.edu.hk   
Contact: Hazel Mok    +852 35053990    hazelmok@cuhk.edu.hk   
Sponsors and Collaborators
Chinese University of Hong Kong

Layout table for additonal information
Responsible Party: Timothy Kwok, Professor, Chinese University of Hong Kong
ClinicalTrials.gov Identifier: NCT03946930     History of Changes
Other Study ID Numbers: 2018.274
First Posted: May 13, 2019    Key Record Dates
Last Update Posted: May 13, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Cognitive Dysfunction
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cognition Disorders